Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Huntington's Disease

In brief

PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).

Key facts

Study ID
NCT03225846
Run by
Wave Life Sciences USA, Inc.
People needed
88
Starts
2017-07-17
Expected to finish
2021-05-10
Last updated by the study team
2022-04-25

Who can join

Age: 25 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.